+

US7494664B2 - Composite biomaterials - Google Patents

Composite biomaterials Download PDF

Info

Publication number
US7494664B2
US7494664B2 US10/493,388 US49338805A US7494664B2 US 7494664 B2 US7494664 B2 US 7494664B2 US 49338805 A US49338805 A US 49338805A US 7494664 B2 US7494664 B2 US 7494664B2
Authority
US
United States
Prior art keywords
hydroxyapatite
composite
alginate
collagen fibers
composite biomaterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US10/493,388
Other languages
English (en)
Other versions
US20060172918A1 (en
Inventor
Shinichi Sotome
Toshimasa Uemura
Junzo Tanaka
Masanori Kikuchi
Kenichi Shinomiya
Tetsuya Tateishi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute for Materials Science
Original Assignee
Japan Science and Technology Agency
National Institute of Advanced Industrial Science and Technology AIST
National Institute for Materials Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Science and Technology Agency, National Institute of Advanced Industrial Science and Technology AIST, National Institute for Materials Science filed Critical Japan Science and Technology Agency
Assigned to JAPAN SCIENCE AND TECHNOLOGY AGENCY, NATIONAL INSTITUTE FOR MATERIALS SCIENCE, NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY reassignment JAPAN SCIENCE AND TECHNOLOGY AGENCY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SOTOME, SHINICHI, KIKUICHI, MASANORI, SHINOMIYA, KENICHI, TANAKA, JUNZO, TATEISHI, TETSUYA, UEMURA, TOSHIMASA
Assigned to JAPAN SCIENCE AND TECHNOLOGY AGENCY, NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, NATIONAL INSTITUTE FOR MATERIALS SCIENCE reassignment JAPAN SCIENCE AND TECHNOLOGY AGENCY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KIKUCHI, MASANORI, SHINOMIYA, KENICHI, SOTOME, SHINICHI, TANAKA, JUNZO, TATEISHI, TETSUYA, UEMURA, TOSHIMASA
Publication of US20060172918A1 publication Critical patent/US20060172918A1/en
Application granted granted Critical
Publication of US7494664B2 publication Critical patent/US7494664B2/en
Assigned to NATIONAL INSTITUTE FOR MATERIALS SCIENCE reassignment NATIONAL INSTITUTE FOR MATERIALS SCIENCE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JAPAN SCIENCE AND TECHNOLOGY AGENCY, NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers

Definitions

  • the present invention relates to composite biomaterials comprising hydroxyapatite, collagen, and alginate and a process for producing the same.
  • the present invention relates to novel composite biomaterials having mechanical properties similar to those of natural bones, excellent bioadaptability, and excellent bone-conductivity and a process for producing the same.
  • Implants such as artificial bones or artificial bone fillers are used particularly for treatment of bone defects.
  • Such implants are required to have bioadaptability and bone inductivity in addition to mechanical properties similar to those of natural bones. That is, implants needs to be gradually resorbed after implantation in the body, involved into the bone regeneration cycle, and then substituted for the bones of the subject.
  • Bones of vertebrates are composed of hydroxyapatite and collagen. They forms a specific nanocomposite structure in natural bones characterized in that the c-axis of hydroxyapatite is oriented along the collagen fibers, and this structure imparts bone-specific mechanical properties.
  • Composite biomaterials of hydroxyapatite and collagen having structures and compositions similar to those of natural bones are described in, for example, JP Patent Publication (Kokai) Nos. 7-101708 A (1995) and 11-199209 A (1999), and bone inductivity thereof has been observed to some extent.
  • Alginic acid is a polysaccharide contained in seaweed, which has been heretofore employed in a haemostatic drug or wound dressing. Concerning artificial bones, development of bone fillers comprising ⁇ -TCP in combination with alginate has been reported (Nagata, Shika Zairyou (Dental materials), vol. 16, No. 6, 1997, pp. 479-491). Moreover, alginic acid has been recently reported to help a repair of bones and/or cartilages (e.g., Fragonas et al., Biomaterials 21, 2000, pp. 795-801). Application of alginic acid to a composite of hydroxyapatite and collagen, however, had not yet been attempted. In particular, homogenous incorporation of alginic acid into the composite while maintaining its specific nanocomposite structure involves some difficulties.
  • An object of the present invention is to provide novel composite biomaterials having excellent bioadaptability and bone inductivity in which alginate is homogenously distributed in a composite of hydroxyapatite and collagen having microporous structures similar to those of natural bones and a process for producing the same.
  • the present inventors have conducted concentrated studies in order to attain the above object. As a result, they have succeeded in obtaining a composite in which alginate has been homogenously incorporated by adding alginate to a microporous composite of hydroxyapatite and collagen in a given step and curing the mixture. They have found that this composite had excellent bioadaptability and bone inductivity. This has led to the completion of the present invention.
  • the present invention provides the following (1) to (10).
  • Composite biomaterials which comprise hydroxyapatite, collagen, and alginate and have a microporous structure in which the c-axis of hydroxyapatite is oriented along the collagen fibers.
  • the composite biomaterials of the present invention comprises hydroxyapatite, collagen, and alginate, and at least a part thereof is a microporous structure in which the c-axis of hydroxyapatite is oriented along the collagen fibers.
  • This structure is specific to natural bones, which imparts mechanical properties specific to the composite biomaterials of the present invention.
  • microporous structure refers to a structure similar to that of natural bones in which indefinite numbers of pores (gaps) of approximately several ⁇ m to several tens of ⁇ m are present.
  • the ratio of hydroxyapatite with collagen in the composite biomaterials of the present invention is generally between 60:40 and 90:10, and preferably between 70:30 and 85:15. This is because the ratio thereof needs to approximate the composition of natural bones (75:25).
  • the composite biomaterials of the present invention comprise alginates homogenously distributed therein. This makes the composite biomaterials more valuable for applications as implants and the like.
  • the alginate content in the composite biomaterials of the present invention is 1 to 30% by mass, and preferably 5 to 20% by mass (“% by mass” is hereafter simply referred to as “%”), relative to the total amount of hydroxyapatite and collagen (total mass). Specifically, when the amount of alginate is too small, the strength of the composite becomes insufficient. In contrast, cell invasion into the biomaterials is blocked when the amount thereof is too large.
  • the composite biomaterials of the present invention When used as bone fillers without curing and lyophilization, the composite biomaterials comprise an adequate amount of water, and their water contents can be adequately determined depending on applications.
  • a hydroxyapatite content of 55 to 80%, a collagen content of 10 to 35%, and an alginate content of 1 to 25%, relative to the entire composite biomaterials after lyophilization are preferable.
  • the composite biomaterials of the present invention have porosities (foamed portions) of 5 to 70%, and preferably approximately 10 to 50%, in a water-containing state before lyophilization. After the lyophilization, the composite biomaterials have porosities of at least 80%, and preferably at least 95%. As mentioned above, low porosity results in insufficient cell invasion into the biomaterials after implantation to the body, which in turn decreases bone inductivity and strength of the implants.
  • the lyophilized composite biomaterials of the present invention have gaps (pores) of between 1 ⁇ m and 500 ⁇ m (average diameter) and indefinite numbers of microgaps (micropores) of 1 ⁇ m or smaller. This microporous structure improves cell invasion and bone inductivity after implantation to the body.
  • the process for producing composite biomaterials of the present invention comprises the following steps 1) and 2).
  • Composite biomaterials having microporous structures in which alginates are homogenously distributed in composites of hydroxyapatite and collagen (hereafter referred to as “HAp/Col composite”) can be obtained by this process:
  • a HAp/Col composite used in step 1) preferably has a microporous structure similar to that of natural bones in which the c-axis of hydroxyapatite is oriented along the collagen fibers.
  • Such a composite can be produced in accordance with, for example, the method of Kikuchi et al. (Biomaterials 22, 2000, pp. 1705-1711). More specifically, a composite of interest can be obtained by simultaneously adding a calcium hydroxide solution and an aqueous phosphate solution containing collagen dropwise to a reaction vessel, and dehydrating the resulting sediment.
  • Collagen used herein is not particularly limited. If the molecular weight of collagen is large, however, the strength of a composite becomes insufficient because of steric hindrance. Accordingly, the use of monomeric collagen is preferable. Pepsin-treated atelocollagen is particularly preferable for the composite biomaterials of the present invention because of its monomeric property and low antigenicity.
  • a small amount of physiological saline, deionized water, a phosphate buffer, or the like is initially added to the above mentioned HAp/Col composite, and the resulting mixture is mixed by a homogenizer or other means. More specifically, when free calcium ion exists in the HAp/Col composite, it is sometimes reacted with alginic acid and cause gelatinization. Thus, calcium ion is allowed to adsorb on hydroxyapatite by adding physiological saline or the like, and it needs to avoid reaction with alginic acid.
  • physiological saline or a phosphate buffer When physiological saline or a phosphate buffer is added, ion penetrates the composite, and it is adsorbed on the surface of hydroxyapatite to neutralize its electric charge. This allows homogenous mixing of alginate and HAp/Col composite. Thus, the use of physiological saline or a phosphate buffer is particularly preferable.
  • the amount of physiological saline, or the like, to be added varies depending on the structure and composition of the HAp/Col composite. It is preferably between 2 times and 6 times the total amount of the HAp/Col composite.
  • Alginates used in step 1) are not particularly limited, and sodium salt, potassium salt, and the like can be used.
  • Crosslinked alginate may be used as alginates. Some of the crosslinked alginate has excellent bioabsorbability, and use thereof is more preferable. Alginates can be handled easily if they are prepared as 3-5% aqueous solutions.
  • step 2) gluconic acid and calcium carbonate are neutralized, carbon dioxide is then foamed, and alginic acid is cured by being crosslinked with calcium ion.
  • gluconic acid and calcium carbonate are neutralized, carbon dioxide is then foamed, and alginic acid is cured by being crosslinked with calcium ion.
  • Calcium carbonate used in step 2) is not particularly limited, and it may be a suspension or powder. Also, gluconic acid used in step 2) is not particularly limited.
  • the molar ratio of calcium carbonate to gluconic acid is between 1:3 and 2:3, and preferably about 1:2.
  • the composite biomaterials of the present invention can have desired pore sizes and porosities through regulation of the amount of foaming by adequately adjusting the amounts of calcium carbonate and gluconic acid. When the amounts of calcium carbonate and gluconic acid are too small, gelatinization becomes insufficient. In contrast, an excess amount thereof results in excessive foaming. Too much or too little amount thereof decreases the strength of the composite biomaterials. Accordingly, calcium carbonate is preferably added in an amount of approximately 10% to 100% relative to the total amount of the HAp/Col composite. When only gluconic acid is added in an amount larger than the adequate level, the amount of foaming does not vary, while the crosslinking density is elevated by free calcium ions generated from the partially dissolved hydroxyapatite. Thus, the strength of the implant is enhanced.
  • the gelatinized mixture obtained in step 2) is immersed in a calcium hydrochloride solution or the like to crosslink alginic acid. Attention should be given to the density of crosslinking since cell invasion after implantation to the body will be adversely affected if crosslinking is too dense.
  • the gelatinized mixture obtained in step 2) begins to cure within about several minutes to several tens of minutes, and the composite biomaterials of the present invention can be thus obtained.
  • the composite biomaterials can be used as bone fillers in that state if they are directly implanted to bone defects before curing.
  • the composite biomaterials are injected into a desired mold immediately after the mixing in of gluconic acid, and then molded.
  • lyophilization is carried out.
  • the structures of the composite biomaterials i.e., specific surface areas, porosities, pore (gap) sizes, and the like, can be suitably adjusted by selecting conditions for lyophilization (e.g., temperature, the duration of freezing, or lyophilization in water).
  • the composite biomaterials of the present invention may contain the essential components, i.e., hydroxyapatite, collagen, and alginate, as well as other components within the scope of the present invention.
  • essential components i.e., hydroxyapatite, collagen, and alginate
  • other components within the scope of the present invention.
  • such components include Bone Morphogenetic Proteins, such as BMP2, BMP6, and BMP7, and growth factors, such as bFGF, aFGF, VEGF, and TGF ⁇ .
  • the composite biomaterials of the present invention can be used as bone fillers as they are if they are directly implanted to bone defects before curing.
  • An implant having a desired configuration and shape can be produced by injecting the composite biomaterials into a desired mold immediately after the mixing in of gluconic acid.
  • the composite biomaterials of the present invention become as elastic as sponges and have excellent bioadaptability, bone inductivity, or bone conductivity upon moisture absorption. Specifically, when the biomaterials are implanted in bone tissues, they rapidly fused with the bone tissues, and integrated into the hard tissue of the recipient.
  • the composite biomaterials of the present invention can be used as a scaffold for cell and/or tissue culture.
  • bone marrow, liver, and other tissues can be reconstructed by conducting tissue culture using the composite biomaterials of the present invention containing highly bioactive cytokines as a scaffold under the biomimetic environment to which dynamics or electricity had been applied.
  • Such scaffold enables effective reconstruction of damaged tissues when they are directly implanted in the body.
  • the composite biomaterials of the present invention can be used as sustained release agents for other bioactive substances, drugs, and the like.
  • the composite materials of the present invention impregnated with anti-cancer agents are used for reconstructing bones resected due to osteogenic sarcoma, carcinoma recurrence can be prevented and the generation of hard tissue in the organism can be induced.
  • the composite materials of the present invention can be utilized as, for example, materials for bone regeneration capable of inducing and conducting bones, scaffold for bioactive agents or cell culture in tissue engineering containing amino acids, saccharides, and cytokines, and biocompatible drug carriers for sustained release.
  • Specific examples of applications include artificial bones, artificial joints, cements for tendons and bones, dental implants, percutaneous terminals for catheters, drug carriers for sustained release, chambers for bone marrow induction, and chambers or scaffolds for tissue reconstruction.
  • FIG. 1 is a scanning microscope photograph of the implant prepared in Example 1.
  • FIG. 2 is a photograph showing an image of HE-stained tissues 2, 4, and 8 weeks after the implantation of the implant of the present invention in Example 2.
  • FIG. 3 is a photograph showing an image of HE-stained tissues 2, 4, and 8 weeks after the implantation of commercialized porous HAp in Example 2.
  • FIG. 4 is a photograph showing an image of HE-stained tissues 2, 4, and 8 weeks after the implantation of a HAp/Col composite in Example 2.
  • FIG. 5 is a photograph showing an image of HE-stained tissues 2, 4, and 8 weeks after the implantation of sodium alginate in Example 2.
  • HAp/Col composite powders 500 mg were used as composites of hydroxyapatite and collagen (HAp/Col composites).
  • the implants were found to be porous bodies having pores of several ⁇ m to several hundreds of ⁇ m (diameter) and had microporous structures similar to those of natural bones ( FIG. 1 ).
  • FIGS. 2 to 5 show the results of HE staining 2, 4, and 8 weeks after implantation of each sample.
  • the implants (composite biomaterials) of the present invention were found to have bioadaptability, the capacity for cell invasion, and the capacity for osteogenesis better than other porous substances.
  • the composite biomaterials of the present invention were found to be excellent in terms of safety since no inflammatory reaction was observed after implantation.
  • the present invention provides novel composite biomaterials having excellent bioadaptability and bone inductivity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Composite Materials (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials For Medical Uses (AREA)
US10/493,388 2001-10-25 2002-09-27 Composite biomaterials Expired - Fee Related US7494664B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001328167 2001-10-25
JP2001-328167 2001-10-25
PCT/JP2002/010036 WO2003035128A1 (fr) 2001-10-25 2002-09-27 Substance biologique composite

Publications (2)

Publication Number Publication Date
US20060172918A1 US20060172918A1 (en) 2006-08-03
US7494664B2 true US7494664B2 (en) 2009-02-24

Family

ID=19144274

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/493,388 Expired - Fee Related US7494664B2 (en) 2001-10-25 2002-09-27 Composite biomaterials

Country Status (4)

Country Link
US (1) US7494664B2 (fr)
JP (1) JP3770555B2 (fr)
CA (1) CA2467252C (fr)
WO (1) WO2003035128A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100158976A1 (en) * 2007-02-09 2010-06-24 Royal College Of Surgeons In Ireland Collagen/hydroxyapatite composite scaffold, and process for the production thereof
US9358122B2 (en) 2011-01-07 2016-06-07 K2M, Inc. Interbody spacer
US9370469B2 (en) 2014-03-14 2016-06-21 Suneva Medical, Inc Injectable alloplastic implants and methods of use thereof
US9370603B2 (en) 2014-03-14 2016-06-21 Suneva Medical, Inc. Injectable alloplastic implants and methods of use thereof

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217294B2 (en) * 2003-08-20 2007-05-15 Histogenics Corp. Acellular matrix implants for treatment of articular cartilage, bone or osteochondral defects and injuries and method for use thereof
KR101187578B1 (ko) * 2004-10-28 2012-10-02 호야 가부시키가이샤 아파타이트/콜라겐 복합체 섬유를 함유하는 다공체의제조방법
JP2007050084A (ja) * 2005-08-17 2007-03-01 National Institute For Materials Science 骨再建材の製造方法および骨再建材ならびに骨組織誘導方法
JP2007098118A (ja) * 2005-09-09 2007-04-19 National Institute For Materials Science 多孔質弾性複合材料の製造方法および多孔質弾性複合材料
JP5024780B2 (ja) * 2005-09-09 2012-09-12 独立行政法人物質・材料研究機構 一方向性多孔質複合体の製造方法および一方向性多孔質複合体
US8282911B2 (en) * 2006-10-23 2012-10-09 ETH Zürich Implant material
CN100438927C (zh) * 2006-11-24 2008-12-03 清华大学 一种海藻酸钙基可注射原位固化骨修复材料的制备方法
JP5458237B2 (ja) * 2008-04-02 2014-04-02 ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 アパタイト／コラーゲン複合体からなる膨張性多孔体、及びその製造方法
US8741053B2 (en) 2009-04-17 2014-06-03 Hoya Technosurgical Corporation Calcium phosphate cement composition and its kit for bone prosthesis
DE112010001636T5 (de) * 2009-04-17 2012-06-21 Hoya Corp. Calciumphosphat-Zementzusammensetzung und deren Kit für eine Knochenprothese
EP2456475B1 (fr) * 2009-07-23 2020-06-24 NuVasive Netherlands B.V. Matériaux ostéoinductifs injectables
EP2529764A1 (fr) 2011-05-31 2012-12-05 Curasan AG Matériau composite biodégradable
CN102406965B (zh) * 2011-12-01 2015-06-24 广西南宁博恩康生物科技有限公司 一种用于治疗骨缺损的可注射凝胶材料及其制备方法
US9821089B2 (en) 2012-02-09 2017-11-21 Ramot At Tel-Aviv University Ltd. Composites comprising collagen extracted from sarcophyton sp. coral
GB2523593A (en) * 2014-02-28 2015-09-02 Adrian Robert Ford Method, design and preparation of a biological implant with enhanced biological activity via modification of the plastic deformation characteristics
EP4024623B1 (fr) 2014-04-24 2024-07-31 Molex, LLC Procédé de fourniture d'un contact de borne

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01207072A (ja) 1988-02-15 1989-08-21 Yasumasa Otori 骨形成材料およびその製法
JPH01299563A (ja) 1988-05-28 1989-12-04 Moritsugu Ootori インプラント材のポーラス部封孔処理方法
WO1998040111A1 (fr) 1997-03-07 1998-09-17 University College London Implant de tissus
US5869080A (en) * 1995-05-30 1999-02-09 Johnson & Johnson Medical, Inc. Absorbable implant materials having controlled porosity
JPH11199209A (ja) 1998-01-19 1999-07-27 Natl Inst For Res In Inorganic Materials 有機無機配向性複合材料の製造方法
US5990381A (en) * 1996-11-13 1999-11-23 Ise International, Co., Ltd. Biomedical materials
WO2000044401A1 (fr) * 1999-01-28 2000-08-03 Hoffmann La Roche Utilisation d'un facteur d'activite inhibitrice de melanome (mia) pour la reparation de cartilages et d'os
US6162258A (en) * 1999-08-25 2000-12-19 Osteotech, Inc. Lyophilized monolithic bone implant and method for treating bone
US6264701B1 (en) * 1994-05-13 2001-07-24 Kensey Nash Corporation Device and methods for in vivo culturing of diverse tissue cells
US6425918B1 (en) * 1996-05-22 2002-07-30 Ben Gurion University Of The Negev Polysaccharide sponges for cell culture and transplantation

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01207072A (ja) 1988-02-15 1989-08-21 Yasumasa Otori 骨形成材料およびその製法
JPH01299563A (ja) 1988-05-28 1989-12-04 Moritsugu Ootori インプラント材のポーラス部封孔処理方法
US6264701B1 (en) * 1994-05-13 2001-07-24 Kensey Nash Corporation Device and methods for in vivo culturing of diverse tissue cells
US5869080A (en) * 1995-05-30 1999-02-09 Johnson & Johnson Medical, Inc. Absorbable implant materials having controlled porosity
US6425918B1 (en) * 1996-05-22 2002-07-30 Ben Gurion University Of The Negev Polysaccharide sponges for cell culture and transplantation
US5990381A (en) * 1996-11-13 1999-11-23 Ise International, Co., Ltd. Biomedical materials
WO1998040111A1 (fr) 1997-03-07 1998-09-17 University College London Implant de tissus
JPH11199209A (ja) 1998-01-19 1999-07-27 Natl Inst For Res In Inorganic Materials 有機無機配向性複合材料の製造方法
WO2000044401A1 (fr) * 1999-01-28 2000-08-03 Hoffmann La Roche Utilisation d'un facteur d'activite inhibitrice de melanome (mia) pour la reparation de cartilages et d'os
US6162258A (en) * 1999-08-25 2000-12-19 Osteotech, Inc. Lyophilized monolithic bone implant and method for treating bone

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
H. Thiele et al.; J. Biomed. Mater. Res., vol. 3, pp. 431-441, 1969. Cited in the PCT search report.
Kikuchi et al., "The biomimetic synthesis and biocompatibility of self-organized hydroxyapatite/collagen composites" Bioceramics 12:393-396, 1999. *
M. Kikuchi et al.; Bioceramics, vol. 12, pp. 393-396, 1999. Cited in the PCT search report.
M. Kikuchi et al.; Materials Research Society, Symposium Proceedings, vol. 599, pp. 51-53, 2000. Cited in the PCT search report.
S. Sotome et al.; The 20th Japanese Society for Transplantation and Tissue Engineering in Musculoskeletal System, 2001.

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100158976A1 (en) * 2007-02-09 2010-06-24 Royal College Of Surgeons In Ireland Collagen/hydroxyapatite composite scaffold, and process for the production thereof
US8435552B2 (en) 2007-02-09 2013-05-07 Royal College Of Surgeons In Ireland Collagen/hydroxyapatite composite scaffold, and process for the production thereof
US9138483B2 (en) 2007-02-09 2015-09-22 Royal College Of Surgeons In Ireland Collagen/hydroxyapatite composite scaffold, and process for the production thereof
US9358122B2 (en) 2011-01-07 2016-06-07 K2M, Inc. Interbody spacer
US9370469B2 (en) 2014-03-14 2016-06-21 Suneva Medical, Inc Injectable alloplastic implants and methods of use thereof
US9370603B2 (en) 2014-03-14 2016-06-21 Suneva Medical, Inc. Injectable alloplastic implants and methods of use thereof
US9789222B2 (en) 2014-03-14 2017-10-17 Suneva Medical, Inc. Injectable alloplastic implants and methods of use thereof

Also Published As

Publication number Publication date
JP3770555B2 (ja) 2006-04-26
JPWO2003035128A1 (ja) 2005-02-10
CA2467252C (fr) 2008-12-02
WO2003035128A1 (fr) 2003-05-01
US20060172918A1 (en) 2006-08-03
CA2467252A1 (fr) 2003-05-01

Similar Documents

Publication Publication Date Title
US7494664B2 (en) Composite biomaterials
JP3727059B2 (ja) 多孔質複合材料の製造方法
US8168151B2 (en) Organic/inorganic composite biomaterials and process for producing the same
AU2008274585B2 (en) Composite bone repair material
JP4680771B2 (ja) リン酸カルシウム含有複合多孔体及びその製造方法
JP4873555B2 (ja) アパタイト／コラーゲン複合体繊維を含む多孔体の製造方法
WO2004041320A1 (fr) Materiau d'apatite/collagene poreux reticule contenant un composite d'apatite/collagene auto-organise et son procede de production
WO2006031196A1 (fr) Composite de matiere de charge biologique poreuse et procede de fabrication correspondant
JPH10151188A (ja) 骨形成用移植体
JP4226830B2 (ja) 複合生体材料の生分解性制御
CN1337271A (zh) 含有纳米相钙磷盐、胶原和海藻酸盐的骨材料的制备方法
Park et al. A bone replaceable artificial bone substitute: morphological and physiochemical characterizations
Murata et al. Bone Engineering-Biological materials and bone morphogenetic proteins
JP2007050084A (ja) 骨再建材の製造方法および骨再建材ならびに骨組織誘導方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: JAPAN SCIENCE AND TECHNOLOGY AGENCY, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SOTOME, SHINICHI;UEMURA, TOSHIMASA;TANAKA, JUNZO;AND OTHERS;REEL/FRAME:016138/0779;SIGNING DATES FROM 20041227 TO 20041228

Owner name: NATIONAL INSTITUTE FOR MATERIALS SCIENCE, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SOTOME, SHINICHI;UEMURA, TOSHIMASA;TANAKA, JUNZO;AND OTHERS;REEL/FRAME:016138/0779;SIGNING DATES FROM 20041227 TO 20041228

Owner name: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SOTOME, SHINICHI;UEMURA, TOSHIMASA;TANAKA, JUNZO;AND OTHERS;REEL/FRAME:016138/0779;SIGNING DATES FROM 20041227 TO 20041228

AS Assignment

Owner name: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SOTOME, SHINICHI;UEMURA, TOSHIMASA;TANAKA, JUNZO;AND OTHERS;REEL/FRAME:016776/0903

Effective date: 20041227

Owner name: JAPAN SCIENCE AND TECHNOLOGY AGENCY, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SOTOME, SHINICHI;UEMURA, TOSHIMASA;TANAKA, JUNZO;AND OTHERS;REEL/FRAME:016776/0903

Effective date: 20041227

Owner name: NATIONAL INSTITUTE FOR MATERIALS SCIENCE, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SOTOME, SHINICHI;UEMURA, TOSHIMASA;TANAKA, JUNZO;AND OTHERS;REEL/FRAME:016776/0903

Effective date: 20041227

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: NATIONAL INSTITUTE FOR MATERIALS SCIENCE, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JAPAN SCIENCE AND TECHNOLOGY AGENCY;NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY;REEL/FRAME:028716/0524

Effective date: 20120731

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20170224

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载